Holen Sie sich die Stockscreener-App
9.5305
0.74%
0.0805
Schlusskurs vom Vortag:
$9.45
Offen:
$9.45
24-Stunden-Volumen:
444.59K
Relative Volume:
0.36
Marktkapitalisierung:
$696.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.60M
KGV:
-3.3648
EPS:
-2.8324
Netto-Cashflow:
$-67.37M
1W Leistung:
+14.42%
1M Leistung:
+16.24%
6M Leistung:
+117.35%
1J Leistung:
+14.84%
1-Tages-Spanne:
$9.12
$9.68
1-Wochen-Bereich:
$8.30
$9.705
52-Wochen-Spanne:
$1.45
$10.38
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Vergleichen Sie LXEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
9.54 | 689.73M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Eingeleitet | Guggenheim | Buy |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Portfolio Update: Why Lexeo Therapeutics Inc stock remains resilientJuly 2025 Review & Real-Time Buy Signal Notifications - BỘ NỘI VỤ
How resilient is Lexeo Therapeutics Inc. stock in market downturnsTreasury Yields & Fast Entry High Yield Stock Tips - Newser
Lexeo Therapeutics (Nasdaq: LXEO) plans virtual PKP2-ACM event at 22nd CVCT Forum Dec. 9 - Stock Titan
Why Lexeo Therapeutics Inc. stock remains resilientWeekly Stock Summary & Accurate Buy Signal Alerts - Newser
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 7.8%What's Next? - MarketBeat
A look into Lexeo Therapeutics Inc (LXEO)’s deeper side - Setenews
Lexeo Therapeutics (NASDAQ:LXEO) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target By Investing.com - Investing.com Canada
Will Lexeo Therapeutics Inc. stock deliver shareholder valueExit Point & Consistent Income Trade Ideas - moha.gov.vn
Why Lexeo Therapeutics Inc. stock is a must watch in 2025July 2025 Patterns & Expert Approved Momentum Ideas - BỘ NỘI VỤ
Paradigm Biocapital Advisors LP Acquires Significant Stake in Le - GuruFocus
LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView
Research Analysts Set Expectations for LXEO FY2025 Earnings - Defense World
Savant Capital LLC Invests $119,000 in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 1,127 Shares of Stock - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock By Investing.com - Investing.com Australia
Lexeo Therapeutics CEO Makes Significant Stock Sale! - TipRanks
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeu - GuruFocus
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock - Investing.com
Lexeo Therapeutics CEO Sells Shares to Cover Tax Obligations - TradingView
CEO Townsend Surrenders 1,127 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Cantor Fitzgerald Initiates Coverage on Lexeo Therapeutics With Overweight Rating, $19 Price Target - MarketScreener
Equities Analysts Set Expectations for LXEO FY2025 Earnings - MarketBeat
HC Wainwright Has Optimistic Outlook of LXEO FY2025 Earnings - Defense World
Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process - MSN
Real time pattern detection on Lexeo Therapeutics Inc. stockMarket Activity Recap & Precise Entry and Exit Recommendations - newser.com
Using Ichimoku Cloud for Lexeo Therapeutics Inc. technicalsWeekly Market Summary & Real-Time Volume Triggers - newser.com
Will Lexeo Therapeutics Inc. price bounce be sustainableGold Moves & Daily Entry Point Alerts - newser.com
Using data models to predict Lexeo Therapeutics Inc. stock movementQuarterly Trade Review & Reliable Entry Point Alerts - newser.com
Officer Tai Files To Sell 386 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Institutional Investors Are Lexeo Therapeutics, Inc.'s (NASDAQ:LXEO) Biggest Bettors and Were Rewarded After Last Week's US$70m Market Cap Gain - 富途牛牛
Lexeo Therapeutics Insiders Benefitted From Selling Stock At US$7.01 - simplywall.st
Optimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety Profile - TipRanks
V2Y Corporation Ltd Expands into Renewable Energy and Commodities - The Globe and Mail
Can Lexeo Therapeutics Inc. stock withstand economic slowdownWeekly Trend Summary & Stock Portfolio Risk Management - newser.com
Using data filters to optimize entry into Lexeo Therapeutics Inc.Portfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Is Lexeo Therapeutics Inc. meeting your algorithmic filter criteriaTrade Risk Assessment & Fast Moving Stock Trade Plans - newser.com
Long term hold vs stop loss in Lexeo Therapeutics Inc.July 2025 Opening Moves & Entry and Exit Point Strategies - newser.com
Best data tools to analyze Lexeo Therapeutics Inc. stockQuarterly Trade Summary & Weekly Chart Analysis and Trade Guides - newser.com
Should you hold or exit Lexeo Therapeutics Inc. now2025 Fundamental Recap & Precise Trade Entry Recommendations - newser.com
How Lexeo Therapeutics Inc. stock reacts to bond yieldsJuly 2025 Movers & Weekly Chart Analysis and Guides - newser.com
Using Python tools to backtest Lexeo Therapeutics Inc. strategiesMarket Sentiment Summary & AI Based Trade Execution Alerts - newser.com
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
Nov 18 '25 |
Sale |
9.27 |
615 |
5,701 |
72,646 |
| See Tai Sandi | Chief Development Officer |
Nov 18 '25 |
Sale |
9.27 |
386 |
3,578 |
65,476 |
| Robertson Jenny | Chief Legal Officer |
Nov 18 '25 |
Sale |
9.27 |
549 |
5,089 |
68,381 |
| Otero Jose Manuel | Chief Technical Officer |
Aug 18 '25 |
Sale |
9.27 |
721 |
6,684 |
63,476 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):